ChemicalBook >> CAS DataBase List >>UZARIN
UZARIN
- CAS No.
- 20231-81-6
- Chemical Name:
- UZARIN
- Synonyms
- UZARIN;Uzarin-RM;uzarigenin+2-d-glucose;anosyl)oxy)-14-hydroxy-;5-alpha-card-20(22)-enolide,3-beta-((6-o-beta-d-glucopyranosyl-beta-d-glucopyr;3β-[(6-O-β-D-Glucopyranosyl-β-D-glucopyranosyl)oxy]-14-hydroxy-5α-card-20(22)-enolide;Card-20(22)-enolide, 3-[(2-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-14-hydroxy-, (3β,5α)-;(3beta,5alpha)-3-[(6-O-beta-D\-glucopyranosyl-beta-D\-glucopyranosyl)oxy]-14-hydroxycard-20(22)-enolide
- CBNumber:
- CB3246508
- Molecular Formula:
- C35H54O14
- Molecular Weight:
- 698.8
- MDL Number:
- MFCD00017376
- MOL File:
- 20231-81-6.mol
Last updated:2025-01-27 09:38:02
| Melting point | 266-270°; mp 206-208° |
|---|---|
| alpha | D20 -27° (c = 1.075 in pyridine); D19 -1.4° (c = 0.85 in methanol) |
| Boiling point | 622.41°C (rough estimate) |
| Density | 1.1645 (rough estimate) |
| refractive index | 1.6130 (estimate) |
| storage temp. | 2-8°C |
| pka | 12.85±0.70(Predicted) |
| form | solid |
| biological source | plant |
| FDA UNII | 68P16H9S6Y |
| UNSPSC Code | 41116107 |
| NACRES | NA.25 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS06,GHS08 |
|---|---|
| Signal word | Danger |
| Hazard statements | H300+H330-H373 |
| Precautionary statements | P260-P264-P284-P301+P310+P330-P304+P340+P310-P403+P233 |
UZARIN price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich | PHL80833 | Uzarin phyproof? Reference Substance | 20231-81-6 | 10MG | $574 | 2024-03-01 | Buy |
| Biosynth Carbosynth | FU137815 | Uzarin | 20231-81-6 | 25mg | $1100 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FU137815 | Uzarin | 20231-81-6 | 50mg | $1650 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FU137815 | Uzarin | 20231-81-6 | 100mg | $3000 | 2021-12-16 | Buy |
| Biosynth Carbosynth | FU137815 | Uzarin | 20231-81-6 | 5mg | $325 | 2021-12-16 | Buy |
UZARIN Chemical Properties,Uses,Production
Uses
It is a natural product derived from plant source th at finds application in compound screening libraries, metabolomics, phytochemical, and pharmaceutical research.
Biological Activity
According to the existing research, Uzarin plays potential role as an inhibitor of the SARS-CoV-2 receptor binding domain and SARS-CoV-2 RNA-dependent polymerase, as indicated by molecular docking and dynamics studies.
UZARIN Preparation Products And Raw materials
Raw materials
Preparation Products
UZARIN Suppliers
Global( 10)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | support@targetmol.com | United States | 38631 | 58 | |
| Sichuan Wei Keqi Biological Technology Co., Ltd. | 028-81700200 18116577057 | 3003855609@qq.com | China | 7787 | 56 |
| Shaanxi Dideu Newmaterial Co., Ltd. | 029-87576359 15353716720 | 1039@dideu.com | China | 10009 | 58 |
| SHANGHAI ZZBIO CO., LTD. | 15102117276 19921389125 | tech@zzbioco.com | China | 12065 | 58 |
| 58896805 | 7993601name@qq.com | CHINA | 15620 | 58 | |
| Carbosynth | -- | sales@carbosynth.com | United Kingdom | 6005 | 58 |
| Supplier | Advantage |
|---|---|
| TargetMol Chemicals Inc. | 58 |
| Sichuan Wei Keqi Biological Technology Co., Ltd. | 56 |
| Shaanxi Dideu Newmaterial Co., Ltd. | 58 |
| SHANGHAI ZZBIO CO., LTD. | 58 |
| 58 | |
| Carbosynth | 58 |
20231-81-6(UZARIN)Related Search:
2,6-DIMETHYLCYCLOHEXANOL
4-N-PROPYL-4-HEPTANOL
4-METHYL-2-PENTENOIC ACID
Batyl alcohol
2-UNDECENOIC ACID
Ethylene Glycol Dibutyl Ether
2-NONENOIC ACID
10-Hydroxy-2-decenoic acid
Methyl trans-2-nonenoate
DL-Menthol
1of4
3β-[(6-O-β-D-Glucopyranosyl-β-D-glucopyranosyl)oxy]-14-hydroxy-5α-card-20(22)-enolide
5-alpha-card-20(22)-enolide,3-beta-((6-o-beta-d-glucopyranosyl-beta-d-glucopyr
anosyl)oxy)-14-hydroxy-
uzarigenin+2-d-glucose
UZARIN
(3beta,5alpha)-3-[(6-O-beta-D\-glucopyranosyl-beta-D\-glucopyranosyl)oxy]-14-hydroxycard-20(22)-enolide
Card-20(22)-enolide, 3-[(2-O-β-D-glucopyranosyl-β-D-glucopyranosyl)oxy]-14-hydroxy-, (3β,5α)-
Uzarin-RM
20231-81-6